Q2 - Novozymes

More documents

Recommendations

Info

The <strong>Novozymes</strong> business caseBiotech-based world leader in enzymes & microorganisms...with a unique triple leverage on its biotech expertise• Innovation-driven topline growthNew products, applications, markets, all expanding the use of industrial biotechnologywith a green, sustainable potential• Continued productivity growthSystematic production optimisation provides higher profitability and asset productivity;liberates capacity, delays investments, ensures high cash flow• Opportunities in new areasStrategy to leverage expertise outside enzymes - acquisition-based microorganismbusiness and projects in biopolymers and biopharmaceuticals….and high profitability and cash flow• 2005 sales of ~USD 1 billion, operating margin of 19.2%, free cash flow 16% of salesand return on invested capital of 19.3%Unlocking the magic of nature24
New products, applications and marketsdeliver sales growth and profitability1990-2005 net sales CAGR of 8%7.0006.0005.000Sales and EBIT margin developmentSalesOperating marginMargin increasedespite currency20%18%16%14%DKK million4.0003.0002.0001.00012%10%8%6%4%2%Per cent01990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005Year0%25Unlocking the magic of nature
Page 2 and 3: Key messages in 1H 2006• Healthy
Page 4 and 5: Detergent enzymes - business update
Page 6: Food enzymes - business update• S
Page 10 and 11: R&D news• Confident outlook for t
Page 13 and 14: Currency risk management• Favoura
Page 15 and 16: Business development update• Over
Page 17 and 18: GroPep acquisition proposalNovozyme
Page 19 and 20: Forward-looking statementsThis pres
Page 21 and 22: Novozymes - brief introduction• D
Page 23: Enzymes and microorganisms are used
Page 27 and 28: Current business composition- new p
Page 29 and 30: Novozymes strategy•New productsEn
Page 31 and 32: All long-term financial targets met
Page 33 and 34: Balance sheetDKK millionFixed asset
Page 35 and 36: How we produce enzymes? (I/II)Micro
Page 37 and 38: GroPep proposal - Strategy & ration
Page 39 and 40: GroPep financial figuresGroPep key
Page 41 and 42: Recognised as a leader in sustainab
Page 43: Biotech-based world leaderin enzyme

Q2 - Novozymes

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?